RTP Mobile Logo
Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia
Released February 2020

Proceedings from Part 1 of a 2-part satellite symposia series during the 61st ASH Annual Meeting. Featuring perspectives from Dr Jeremy Abramson, Dr Bruce D Cheson, Prof John G Gribben, Dr Brad S Kahl, Dr Loretta Nastoupil and Dr Laurie H Sehn. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphomas and chronic lymphocytic leukemia (CLL).

    OVERVIEW OF ACTIVITY
    Hematologic cancers include the lymphomas, the leukemias, multiple myeloma and other related disorders stemming from lymphoid and myeloid progenitor cell lines. Taken together, it is estimated that approximately 176,200 new lymphoid, myeloid and leukemic cancer cases were identified in the United States in the year 2019, and 56,770 individuals died from these diseases. Importantly, more than 70 drug products are currently labeled for use in the management of hematologic cancers with more than 120 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of their appropriate application across a vast spectrum of tumor types. This is particularly true for lymphomas and CLL, where the past several years have yielded a staggering number of important clinical and research advances.

    These proceedings from a CME symposium during the ASH Annual Meeting use the perspectives of a group of community oncologists/hematologists gathered during a daylong working group to establish and subsequently address some of the most frequently encountered questions and controversies facing clinicians involved in the management of these diseases. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphomas and CLL with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Review recent therapeutic advances and related FDA authorizations for newly diagnosed and relapsed/refractory mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and CLL, and use this information to counsel patients regarding protocol and off-protocol therapy.
    • Consider published Phase III efficacy and safety data evaluating the use of BTK inhibition as first-line therapy for patients with CLL, and use this information to discern how, if at all, these strategies can be optimally integrated into nonresearch care algorithms.
    • Recall the biologic rationale for, available research evidence with and ongoing research efforts evaluating the use of chemotherapy-free combinations for newly diagnosed and progressive FL, CLL and MCL to prepare for their potential introduction into the practical management of these diseases.
    • Develop an understanding of the biologic rationale for and appreciate available efficacy and safety data with chimeric antigen receptor T-cell therapy, and identify patients with relapsed/refractory B-cell lymphomas for whom this approach may be appropriate.
    • Describe available and emerging data with other investigational agents and immunotherapeutic strategies currently under evaluation for MCL, DLBCL, FL and CLL, and where applicable, refer eligible patients for trial participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASHNHL19/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Jeremy Abramson, MD
    Director, Center for Lymphoma
    Massachusetts General Hospital
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: AbbVie Inc, Celgene Corporation, EMD Serono Inc, Genentech, Janssen Biotech Inc, Roche Laboratories Inc; Contracted Research: Celgene Corporation, Seattle Genetics.

    Bruce D Cheson, MD
    Frank M Ewing Foundation Chair in Hematology-Oncology
    Professor of Medicine
    Head of Hematology and Cellular Therapy
    Deputy Chief, Division of Hematology-Oncology
    Georgetown University Hospital
    Lombardi Comprehensive Cancer Center
    Washington, DC

    Advisory Committee: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Dr Reddy’s Laboratories Ltd, Epizyme, Genentech, Gilead Sciences Inc, Karyopharm Therapeutics, MorphoSys, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, SymBio Pharmaceuticals Limited, TG Therapeutics Inc; Consulting Agreements: Astellas, Karyopharm Therapeutics, MorphoSys, Parexel International Corporation, SymBio Pharmaceuticals Limited; Contracted Research: AbbVie Inc, Adaptive Biotechnologies, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Gilead Sciences Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seattle Genetics, TG Therapeutics Inc, Trillium Therapeutics Inc.

    Prof John G Gribben, MD, DSc, FMedSci
    Chair of Medical Oncology
    Barts Cancer Institute
    Queen Mary University of London
    Charterhouse Square
    London, United Kingdom

    Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Janssen Biotech Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP; Symposium Presentations: AbbVie Inc, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Roche Laboratories Inc.

    Brad S Kahl, MD
    Professor of Medicine
    Washington University School of Medicine
    Director, Lymphoma Program
    Siteman Cancer Center
    St Louis, Missouri

    Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, BeiGene, Celgene Corporation, Genentech, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc.

    Loretta Nastoupil, MD
    Associate Professor
    Department of Lymphoma/Myeloma
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech, Gilead Sciences Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Novartis, Spectrum Pharmaceuticals Inc, TG Therapeutics Inc; Consulting Agreements: Celgene Corporation, Gilead Sciences Inc, Merck, Novartis; Contracted Research: Celgene Corporation, Genentech, Janssen Biotech Inc, Karus Therapeutics, LAM Therapeutics, Merck, TG Therapeutics Inc; Data and Safety Monitoring Board/Committee: Denovo Biopharma.

    Laurie H Sehn, MD, MPH
    Chair, Lymphoma Tumour Group
    BC Cancer Centre for Lymphoid Cancer
    Associate Editor, Blood
    Vancouver, Canada

    Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Amgen Inc, Apobiologix, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, Kite Pharma Inc, Lundbeck, Merck, MorphoSys, Roche Laboratories Inc, Seattle Genetics, Takeda Oncology, Teva Oncology, TG Therapeutics Inc; Contracted Research: Genentech, Roche Laboratories Inc.

    CONSULTING ONCOLOGISTS/HEMATOLOGISTS — The following consulting oncologists/hematologists (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Warren S Brenner, MD
    Lynn Cancer Institute
    Boca Raton, Florida

    Speakers Bureau: Celgene Corporation, Takeda Oncology.

    Gautam Kale, MD, MS
    Hematology (Lead) and Oncology Staff Physician
    Cone Health Cancer Center
    Greensboro, North Carolina

    No relevant conflicts of interest to disclose.

    Khuda Dad Khan, MD, PhD
    Hematology, Oncology, Immunology
    Norton Cancer Institute
    Norton Audubon Hospital
    Louisville, Kentucky

    Consulting Agreement: Novartis; Speakers Bureau: Alexion Pharmaceuticals, Genentech, Novartis.

    Zanetta S Lamar, MD
    Florida Cancer Specialists and Research Institute
    Naples, Florida

    No relevant conflicts of interest to disclose.

    Neil Morganstein, MD
    Hematology Oncology
    Atlantic Health System
    Summit, New Jersey

    No relevant conflicts of interest to disclose.

    Namrata I Peswani, MD
    Hematology Oncology/Palliative Care
    Advocate Medical Group
    Orland Park, Illinois

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Gilead Sciences Inc, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: February 2020
    Expiration date: February 2021

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Introduction

Evolving Therapeutic Algorithms for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL)

Management of Relapsed/Refractory (R/R) CLL and Novel Investigational Approaches

Contemporary Management of Newly Diagnosed and R/R Follicular Lymphoma (FL)

Protocol and Off-Protocol Care for Patients with Mantle Cell Lymphoma (MCL)

Recent Breakthroughs and Other Promising Approaches in the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

Integration of CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Lymphomas

Select Publications